CLEU19017 / S1712 / Kristen O'DwyerResearch Question:
How well does ruxolitinib phosphate and dasatinib or nilotinib work in treating patients
with chronic myeloid leukemia?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib,
dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia.
Chronic myeloid leukemia cells produce a protein called BCR-ABL. The BCR-ABL protein
helps chronic myeloid leukemia cells to grow and divide. Tyrosine kinase inhibitors,
such as bosutinib, dasatinib, and nilotinib, stop the BCR-ABL protein from working,
which helps to reduce the amount of chronic myeloid leukemia cells in the body. Ruxolitinib
is a different type of drug that helps to stop the body from making substances called
growth factors. Chronic myeloid leukemia cells need growth factors to grow and divide.
The addition of ruxolitinib to the tyrosine kinase inhibitor may or may not help reduce
the amount of chronic myeloid leukemia cells in the body.
Study Reference #: cleu19017
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amber Johnson
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search